Friedreich's ataxia: clinical features, pathogenesis and management.
Cook A, Giunti P.
Br Med Bull. 2017 Dec 1;124(1):19-30. doi: 10.1093/bmb/ldx034.
Friedreich ataxia: clinical features and new developments.
Keita M, McIntyre K, Rodden LN, Schadt K, Lynch DR.
Neurodegener Dis Manag. 2022 Oct;12(5):267-283. doi: 10.2217/nmt-2022-0011. Epub 2022 Jun 29.
Friedreich ataxia- pathogenesis and implications for therapies.
Delatycki MB, Bidichandani SI.
Neurobiol Dis. 2019 Dec;132:104606. doi: 10.1016/j.nbd.2019.104606. Epub 2019 Sep 5.
Friedreich's ataxia-a rare multisystem disease.
Reetz K, Lischewski SA, Dogan I, Didszun C, Pishnamaz M, Konrad K, Marx-Schütt K, Farmer J, Lynch DR, Corben LA, Pandolfo M, Schulz JB; FACROSS study group.
Lancet Neurol. 2025 Jul;24(7):614-624. doi: 10.1016/S1474-4422(25)00175-9.
Clinical features of Friedreich's ataxia: classical and atypical phenotypes.
Parkinson MH, Boesch S, Nachbauer W, Mariotti C, Giunti P.
J Neurochem. 2013 Aug;126 Suppl 1:103-17. doi: 10.1111/jnc.12317.
Friedreich ataxia.
Johnson WG.
Clin Neurosci. 1995;3(1):33-8.
Friedreich's ataxia.
Alper G, Narayanan V.
Pediatr Neurol. 2003 May;28(5):335-41. doi: 10.1016/s0887-8994(03)00004-3.
Omaveloxolone: a groundbreaking milestone as the first FDA-approved drug for Friedreich ataxia.
Pilotto F, Chellapandi DM, Puccio H.
Trends Mol Med. 2024 Feb;30(2):117-125. doi: 10.1016/j.molmed.2023.12.002. Epub 2024 Jan 24.
Friedreich ataxia.
Pandolfo M.
Semin Pediatr Neurol. 2003 Sep;10(3):163-72. doi: 10.1016/s1071-9091(03)00025-1.
Therapeutic Prospects for Friedreich's Ataxia.
Zhang S, Napierala M, Napierala JS.
Trends Pharmacol Sci. 2019 Apr;40(4):229-233. doi: 10.1016/j.tips.2019.02.001.
